regardless of promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable difficulty from managed care entities. The insurers are often building limitations to coverage, such as high expense requirements and approval processes that restrict patient opportuni